Form 8-K

8-K — Scienture Holdings, Inc.

Accession: 0001493152-26-025062

Filed: 2026-05-22

Period: 2026-05-18

CIK: 0001382574

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001382574

2026-05-18

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 OR 15(d) of the

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): May 18, 2026

SCIENTURE

HOLDINGS, INC.

(Exact

Name of Registrant as Specified in Its Charter)

Delaware

001-39199

46-3673928

(State

or other jurisdiction

incorporation)

(Commission

File

No.)

(I.R.S.

Employer

Identification

No.)

Austin Blvd.

Commack,

NY 11725

(Address

of Principal Executive Offices)

(631)

670-6039

(Registrant’s

Telephone Number)

Not

Applicable

(Former

Name or Former Address, if Changed Since Last Report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

stock, par value $0.00001 per share

SCNX

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

May 18, 2026, Scienture Holdings, Inc. issued a press release announcing its financial results for the quarter ending March 31, 2026,

and other recent operational highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K

and is incorporated herein by reference.

The

information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed”

for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise

subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of

1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Forward

Looking Statements

This

Current Report on Form 8-K contains certain statements that may be deemed to be “forward-looking statements” within the federal

securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are

not historical are forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange.

Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements

are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our

beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our management team’s

expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts

or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In

some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,”

“could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,”

“potential,” “predict,” “project,” “should,” or the negative of these terms or other

similar expressions, but the absence of these words does not mean that a statement is not forward-looking. These

statements are based on our expectations and involve risks, uncertainties and other important factors that could cause our actual results

performance or achievements (or entities in which we have an interest), or industry results, to differ materially from future results,

performance or achievements expressed or implied by such forward-looking statements. Certain factors that could cause our actual future

results to differ materially from those discussed are noted in connection with such statements, but other unanticipated factors (including

those beyond our control) could arise. Certain risks regarding our forward-looking statements are discussed in our filings with the Securities

and Exchange Commission, including an extensive discussion of these risks in our Annual Report on Form 10-K for the year ending December

31, 2025, as amended, and subsequent Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking

statements which reflect management’s view only as of the date of this Current Report on Form 8-K. We undertake no obligation to

publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect

the occurrence of unanticipated events, conditions or circumstances.

Item

9.01. Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit

No.

Description

99.1

Press Release, dated May 18, 2026.

104

Cover

Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

SCIENTURE

HOLDINGS, INC.

By:

/s/

Dr. Narasimhan Mani

Dr.

Narasimhan Mani

Co-Chief

Executive Officer

Date:

May 22, 2026

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit 99.1

SCIENTURE

Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion

COMMACK,

NY, May 18, 2026 (GLOBE NEWSWIRE) — SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for

existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through

the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business

update and reported financial results for the three months ended March 31, 2026.

2026 Financial Highlights Compared to Q1 2025:

●

Revenue

increased to approximately $56 thousand for the three months ended March 31, 2026, compared to approximately $10 thousand in the

prior-year three-month period, representing an increase of approximately 449% year-over-year, reflecting incremental product orders

for ArbliTM in addition to the initial launch quantities ordered in the fourth quarter of 2025

●

Gross

profit increased substantially to approximately $54 thousand, compared to approximately $673 in the prior-year three-month period,

representing an increase of approximately 7900% year-over-year, primarily as a result of the increase in ArbliTM product

orders

●

Gross

margin expanded to approximately 95.6% for the three months ended March 31, 2026, compared to approximately 6.6% in the prior-year

three-month period, also as a result of the increase in ArbliTM product orders

Key

Operational Highlights in Q1 2026 and Subsequent Events:

●

United

States Patent and Trademark Office (USPTO) granted a third patent covering ArbliTM (losartan potassium) oral suspension,

further strengthening the product’s intellectual property portfolio and extending expected market exclusivity through 2041

●

Received

an Orange Book-listable patent for REZENOPYTM (naloxone HCl) nasal spray 10 mg, the highest-dose FDA-approved naloxone

HCl nasal spray for emergency opioid overdose treatment

●

Formalized

multiple commercial GPO agreements for REZENOPYTM, expanding access to over 5,000 healthcare institutions and reaching

approximately 60% of the U.S. institutional market, including first responders, EMS providers, and rehabilitation centers

●

Secured

$11.0 Million in non-dilutive debt financing to accelerate growth of approved product portfolio and advancement of R&D pipeline

Narasimhan

Mani, President and Co-CEO of Scienture, commented, “Our financial results for the quarter reflect the early progress of our commercialization

strategy, with revenue increasing approximately 449% year-over-year to $56 thousand, gross profit increasing approximately 7900% year-over-year

to $54 thousand, and gross margin expanding significantly to approximately 95.6%, compared to 6.6% in the prior-year period. The increase

in revenue and gross margin reflects incremental product orders received for ArbliTM during the first quarter of 2026, following

the significant initial launch quantity orders recorded in the fourth quarter of 2025.”

“During

the quarter, we experienced continued month-over-month growth in both prescriptions and units sold for ArbliTM. We are actively

working to enhance our promotional and commercial activities around the product to further increase physician awareness and market penetration.

We also continue to advance key commercial initiatives to support the planned launch of REZENOPYTM. Our sales force is scheduled

to begin operations on June 1, 2026, targeting key accounts and purchasing organizations, and we have also successfully secured key GPO

contracts that we believe will support broad commercial access and accelerate adoption following launch. Together, we believe the continued

commercialization of ArbliTM and the anticipated launch of REZENOPYTM will have a meaningful impact on our business

performance during the second half of 2026,” added Mani.

“In

addition, we recently secured $11.0 million through a non-dilutive debt financing transaction that we believe significantly strengthens

our capital position and provides important financial flexibility as we continue scaling our commercial operations,” stated Shankar

Hariharan, Executive Chairman and co-CEO of Scienture. “We believe this financing will serve as a catalyst to help position the

Company toward anticipated profitability in 2027, while also supporting the continued growth of our commercial product portfolio and

the progression of our R&D pipeline.”

2026 Financial Summary

Revenue

for the year three months ended March 31, 2026 increased 449% to $56 thousand, compared to $10 thousand in the prior year period, driven

by the continued ramp of wholesale distribution sales of SCN-102 (ArbliTM) following its commercial launch. Gross profit increased

to approximately $54 thousand, compared to approximately $673 in the prior-year period, representing year-over-year growth of approximately

7900%.

Total

operating expenses remained relatively consistent at approximately $3.56 million for the period ended March 31, 2026, compared to approximately

$3.57 million in the prior-year period, representing a slight decrease of approximately 0.2% year-over-year. Net loss was approximately

$3.4 million for the period ended March 31, 2026, compared to approximately $3.1 million in the prior-year period.

About

ArbliTM

is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first

and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf

life at room temperature storage. ArbliTM is FDA-approved for the treatment of hypertension in patients greater than six years

old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy

in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, ArbliTM provides

a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, ArbliTM provides

consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan

prescriptions. ArbliTM has two issued patents from the USPTO, which are also listed in the FDA Orangebook.

ArbliTM

is the first and only oral liquid formulation of losartan approved by the U.S. FDA. ArbliTM comes in a 165 mL bottle as a

peppermint flavored suspension that does not require refrigeration and has been approved for a shelf life of 24 months from the date

of manufacture when stored at room temperature.

INDICATION

ArbliTM

is an angiotensin II receptor blocker (ARB) indicated for:

●

Treatment

of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk

of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.

●

Reduction

of the risk of stroke in patients with hypertension and left ventricular hypertrophy.

●

Treatment

of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.

IMPORTANT

SAFETY INFORMATION

●

not take ArbliTM when pregnant. When pregnancy is detected, discontinue ArbliTM as soon as possible. Drugs

that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ArbliTM can

cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and

third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.

●

not co-administer ArbliTM with aliskiren in patients with diabetes. Avoid use of aliskiren with ArbliTM in

patients with renal impairment (GFR <60 mL/min).

●

not administer ArbliTM in patients with severe hepatic impairment. ArbliTM has not been studied in patients

with severe hepatic impairment.

●

The

most common adverse reactions are (incidence ≥2% and greater than placebo): dizziness, upper respiratory infection, nasal congestion,

and back pain.

You

are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also contact Scienture at 1-833-754-4917.

Please

see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider.

About

Hypertension

(high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According

to the CDC, hypertension, or high blood pressure, affects nearly half of adults in the United States, or approximately 119.9 million

people. Hypertension is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher.

Hypertension is a risk factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk

of having high blood pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and

drinking too much alcohol. Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic

blood pressure readings on both days is ≥140 mmHg and/or the diastolic blood pressure readings on both days is ≥ 90 mmHg.

About

REZENOPYTM

(naloxone HCl) Nasal Spray 10mg, is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose,

as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for immediate administration

as emergency therapy in settings where opioids may be present.

REZENOPYTM

nasal spray is for intranasal use only and is supplied as a carton containing two (2) blister packages each with a single spray device.

IMPORTANT

SAFETY INFORMATION

REZENOPYTM

(naloxone hydrochloride) Nasal Spray 10 mg is an opioid antagonist indicated for the emergency treatment of known or suspected opioid

overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for immediate

administration as emergency therapy in settings where opioids may be present and is not a substitute for emergency medical care.

Important

Safety Information

●

Contraindications:

REZENOPYTM nasal spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of

the other ingredients.

●

Warnings

and Precautions:

●

Risk

of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under

continued surveillance and administer additional doses as necessary while awaiting emergency medical assistance.

●

Risk

of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists

or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.

●

Precipitation

of Severe Opioid Withdrawal: Use in patients who are opioid-dependent may precipitate opioid withdrawal. In neonates, opioid withdrawal

may be life-threatening if not recognized and properly treated. Monitor for the development of opioid withdrawal.

●

Risk

of Cardiovascular Effects: Abrupt postoperative reversal of opioid depression may result in adverse cardiovascular effects. These

events have primarily occurred in patients who had pre-existing cardiovascular disorders or received other drugs that may have similar

adverse cardiovascular effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.

●

Adverse

Reactions: The following adverse reactions were observed in a REZENOPYTM nasal spray clinical study: upper abdominal pain,

nasopharyngitis, and dysgeusia.

For

complete product information, including Patient Information, please refer to the full Prescribing Information.

About

Scienture Holdings, Inc.

SCIENTURE

HOLDINGS, INC. (NASDAQ: SCNX), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company

focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market

needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals

who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare

systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and

channels. For more information please visit: www.scientureholdings.com and www.scienture.com.

Cautionary

Statements Regarding Forward-Looking Statements

This

press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities

laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical

are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange

Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking

statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry,

our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management

team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the

success those products may have in the marketplace, such as ArbliTM and REZENOPYTM, and our strategies related

to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances,

including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the

following words: “anticipate,” “believe,” “continue,” “could,” “estimate,”

“expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,”

“project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words

does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties

(some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or

implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These

risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of

such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain

of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Stock Market LLC; claims relating to

alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings

that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed

in our most recent Annual Report on Form 10-K, as amended, and subsequent reports filed with the Securities and Exchange Commission.

Forward-looking

statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking

statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided

by law.

Contact:

SCIENTURE

HOLDINGS, INC.

Austin Blvd

Commack,

NY 11725

Phone:

(866) 468-6535

Email:

IR@Scienture.com

Scienture

Holdings, Inc.

Condensed

Consolidated Balance Sheets

of March 31, 2026 and December 31, 2025

(Unaudited)

March 31,

December 31,

2026

2025

ASSETS

Current assets:

Cash and cash equivalents

$ 3,542,754

$ 6,662,008

Accounts receivable, net

722,545

731,328

Inventory

210,934

213,408

Prepaid expenses

250,427

262,278

Deferred offering costs

47,384

Total current assets

4,774,044

7,916,406

Property, plant and equipment, net

15,000

15,500

Notes receivable

5,000,000

Interest receivable

343,750

250,000

Intangible assets, net

70,519,218

70,973,064

Operating lease right-of-use assets

9,693

23,360

Total assets

$ 80,661,705

$ 84,178,330

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

$ 1,404,794

$ 1,443,266

Accrued liabilities

703,872

657,034

Operating lease liability - current

10,004

24,137

Warrant liability

10,914

Development agreement liability - current portion

685,000

600,000

Total current liabilities

2,803,670

2,735,351

Development agreement liability

285,000

Deferred tax liability

11,037,595

Total liabilities

13,841,265

14,057,946

Commitments and contingencies (Note 15)

Stockholders’ equity:

Series A preferred stock, $0.00001 par value; 0 and 9,211,246 shares authorized; 0 shares issued

and outstanding as of both March 31, 2026 and December 31, 2025

Series B preferred stock, $0.00001 par value; 787,754 shares authorized; 15,759 shares issued

and outstanding as of both March 31, 2026 and December 31, 2025

Series C preferred stock, $0.00001 par value; 1,000 shares authorized; 0 shares issued and

outstanding as of both March 31, 2026 and December 31, 2025

Series X preferred stock, $0.00001 par value; 9,211,246 shares authorized; 0 shares issued and

outstanding as of both March 31, 2026 and December 31, 2025

Common stock, $0.00001 par value; 100,000,000 shares authorized; 40,630,815 and 40,630,815

shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively

1,015,000 and 1,015,000 shares unvested as of March 31, 2026 and December 31, 2025,

respectively

406

Additional paid-in capital

150,773,535

150,671,215

Accumulated deficit

(83,953,501 )

(80,551,237 )

Total stockholders’ equity

66,820,440

70,120,384

Total liabilities and stockholders’ equity

$ 80,661,705

$ 84,178,330

Scienture

Holdings, Inc.

Condensed

Consolidated Statements of Operations

For

the Three Months Ended March 31, 2026 and 2025

(Unaudited)

Three Months Ended

March 31,

2026

2025

Revenues

$ 56,325

$ 10,258

Cost of sales

2,475

9,585

Gross profit

53,850

673

Operating expenses:

Wage and salary expense

420,008

696,068

Professional fees

932,552

412,850

Accounting and legal expense

326,178

470,825

Technology expense

15,763

61,620

General and administrative

1,074,864

1,355,948

Research and development

793,984

574,679

Total operating expenses

3,563,349

3,571,990

Operating loss

(3,509,499 )

(3,571,317 )

Non-operating income (expense):

Change in fair value of warrant liability

10,910

645,986

Change in fair value of derivative liability

603,322

Loss on conversion of note payable

(96,646 )

Interest income

133,344

25,442

Interest expense

(37,019 )

(670,784 )

Total non-operating expense

107,235

507,320

Benefit (provision) for income taxes

Net loss

$ (3,402,264 )

$ (3,063,997 )

Net loss per common share

Basic

$ (0.08 )

$ (0.33 )

Diluted

$ (0.08 )

$ (0.33 )

Weighted average common shares outstanding

Basic

40,630,815

9,425,751

Diluted

40,630,815

9,425,751

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

May 18, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 18, 2026

Entity File Number

001-39199

Entity Registrant Name

SCIENTURE

HOLDINGS, INC.

Entity Central Index Key

0001382574

Entity Tax Identification Number

46-3673928

Entity Incorporation, State or Country Code

Entity Address, Address Line One

Austin Blvd.

Entity Address, City or Town

Commack

Entity Address, State or Province

Entity Address, Postal Zip Code

11725

City Area Code

(631)

Local Phone Number

670-6039

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

stock, par value $0.00001 per share

Trading Symbol

SCNX

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration